LAZANDA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lazanda, and when can generic versions of Lazanda launch?
Lazanda is a drug marketed by Btcp Pharma and is included in one NDA. There are five patents protecting this drug.
This drug has sixty-two patent family members in thirty countries.
The generic ingredient in LAZANDA is fentanyl citrate. There are thirty-one drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the fentanyl citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lazanda
A generic version of LAZANDA was approved as fentanyl citrate by HIKMA on July 11th, 1984.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LAZANDA?
- What are the global sales for LAZANDA?
- What is Average Wholesale Price for LAZANDA?
Summary for LAZANDA
International Patents: | 62 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 34 |
Clinical Trials: | 5 |
Drug Prices: | Drug price information for LAZANDA |
What excipients (inactive ingredients) are in LAZANDA? | LAZANDA excipients list |
DailyMed Link: | LAZANDA at DailyMed |
Recent Clinical Trials for LAZANDA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Joseph Ma | Phase 2 |
University of California, San Diego | Phase 2 |
Depomed | Phase 4 |
US Patents and Regulatory Information for LAZANDA
LAZANDA is protected by five US patents.
Patents protecting LAZANDA
Method of managing or treating pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Method of managing or treating pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Intranasal spray device containing pharmaceutical composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Container
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Intranasal spray device containing pharmaceutical composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-003 | Dec 21, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-002 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-002 | Jun 30, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LAZANDA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-002 | Jun 30, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-001 | Jun 30, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Btcp Pharma | LAZANDA | fentanyl citrate | SPRAY, METERED;NASAL | 022569-002 | Jun 30, 2011 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LAZANDA
See the table below for patents covering LAZANDA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2824385 | RECIPIENT AMELIORE (IMPROVED CONTAINER) | ⤷ Sign Up |
Cyprus | 1115056 | ⤷ Sign Up | |
Portugal | 2436375 | ⤷ Sign Up | |
Japan | 2014511307 | ⤷ Sign Up | |
Denmark | 2670674 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LAZANDA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1635783 | 122014000024 | Germany | ⤷ Sign Up | PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831 |
1769785 | C300522 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006 |
1635783 | 132014902242643 | Italy | ⤷ Sign Up | PRODUCT NAME: FENTANIL IN QUALSIASI FORMA PROTETTA DAL BREVETTO DI BASE(PECFENT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/10/644/001-004, 20100831 |
0836511 | 122006000022 | Germany | ⤷ Sign Up | PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126 |
1635783 | C300653 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |